After spinal cord injury (SCI), a fibrotic scar forms at the injury site that is best characterized by the accumulation of perivascular fibroblasts and deposition of the extracellular matrix protein fibronectin. While fibronectin is a growthpermissive substrate for axons, the fibrotic scar is inhibitory to axon regeneration. The mechanism behind how fibronectin contributes to the inhibitory environment and how the fibronectin matrix is assembled in the fibrotic scar is unknown. By deleting fibronectin in myeloid cells, we demonstrate that fibroblasts are most likely the major source of fibronectin in the fibrotic scar. In addition, we demonstrate that fibronectin is initially present in a soluble form and is assembled into a matrix at 7 d post-SCI. Assembly of the fibronectin matrix may be mediated by the canonical fibronectin receptor, integrin a5b1, which is primarily expressed by activated macrophages/microglia in the fibrotic scar. Despite the pronounced cavitation after rat SCI, fibrotic scar also is observed in a rat SCI model, which is considered to be more similar to human pathology. Taken together, our study provides insight into the mechanism of fibrotic scar formation after spinal cord injury.
Introduction
A fter spinal cord injury (SCI), a scar tissue forms at the injury site that comprises glial and fibrotic components. The glial scar is characterized by extensive astrogliosis surrounding the central core region of the injury site. The fibrotic scar occupies the injury core and is made up of fibroblasts and a dense extracellular matrix (ECM). The scar tissue not only plays a protective role by limiting spreading of inflammation and secondary damage to nearby intact tissue, but it also serves as an inhibitory barrier for axon regeneration. 1, 2 Recent studies of the scar tissue have been mostly focused on the glial scar while the fibrotic component has received less attention. In vitro models of the scar tissue using coculture of astrocytes and meningeal fibroblasts show that the fibrotic scar is inhibitory for axon growth. [3] [4] [5] In vivo ablation of fibroblasts after SCI lead to compromised tissue integrity and cavitation at injury site. 6 Thus, understanding how the fibrotic scar is formed may provide novel insights into SCI pathology.
The fibrotic scar has traditionally been described as areas with high fibronectin immunoreactivity. 7, 8 While fibronectin is not expressed at high levels in the normal adult spinal cord, previous studies suggest that its excess deposition after SCI could come from multiple sources, such as reactive astrocytes, macrophages, and fibroblasts. [9] [10] [11] In addition to serving as a scaffold to which many other extracellular matrix molecules can bind, fibronectin is known to be involved in many cellular functions, including migration, proliferation, and differentiation. [12] [13] [14] Fibronectin is expressed by a single gene with multiple isoforms generated by alternative splicing-the two major types being plasma and cellular fibronectin. Plasma fibronectin is produced by liver hepatocytes and released into the blood where it functions in forming a provisional blood clot that allows cells to migrate into the injury site and perform tissue remodeling for wound repair. During this process, the provisional clot, along with plasma fibronectin, is degraded by infiltrating cells expressing many different isoforms of cellular fibronectin that is assembled into a more stable matrix.
To be a functional matrix, fibronectin needs to polymerize into a fibrillar network, which is initiated by binding to cellular integrin receptors. Upon binding to fibronectin, integrin receptors cluster and bring adjacent fibronectin fibrils close together, thereby promoting their association and formation into a matrix. 11 However, whether or how this fibronectin matrix assembly occurs after SCI is not known.
Penetrating SCI in humans that disrupts dura mater often leads to invasion of meningeal fibroblasts and deposition of a fibrous connective tissue in the lesion core. This is similar to penetrating SCI in mice, as we described previously. 15 However, the most prevalent type of SCI in human patients is contusion, in which the dura remains largely intact and the lesion core often develops fluidfilled cavities. 16, 17 Using a mouse model of contusive SCI, we demonstrated that perivascular fibroblasts detach from blood vessels and form a compact fibrotic scar at the injury site. 15 However, the extent to which this fibrotic scar also is conserved across species is not known, especially in rats that exhibit a similar pathology to human patients with contusive SCI.
In this study, we demonstrate that fibronectin is assembled into a matrix to form the fibrotic scar and this process is likely mediated by the fibronectin receptor integrin a5b1, which is primarily expressed by activated macrophages/microglia. We also show that deletion of fibronectin in myeloid cells does not change fibronectin expression level, indicating that fibroblasts are likely the major source of fibronectin in the fibrotic scar. Finally, we demonstrate the presence of fibrotic markers in a move translational rat contusion model, highlighting the clinical relevance of the fibrotic scar. Overall, our study provides novel insight into the mechanism of fibrotic scar formation after SCI.
Methods

Animals
For our study, lysM-Cre (#004781) mice were obtained from Jackson Labs (Bar Harbor, ME). Col1a1-GFP mice were kindly donated by Dr. David Brenner.
18 Rosa26-tdTomato reporter mice were kindly donated by Dr. Fan Wang. 19 Floxed fibronectin (FN) mice were kindly donated by Dr. Sakai Takao. 20 All mice were backcrossed to C57BL/6 for at least six generations. The lysM-Cre mice were bred to Rosa26-tdTomato reporter mice to generate lysM tdTom in which lysM-Cre is hemizygous and tdTomato is homozygous. The same strategy was used to generate lysM-FN fl/fl mice. Sprague-Dawley rats were obtained from Harlan Laboratories (Dublin, VA).
Surgery and behavioral assessment
Eight-to ten-week-old female mice were anesthetized (ketamine/ xylazine, 100 mg/15 mg/kg intraperitoneally) before receiving midthoracic (T8) contusive spinal cord injuries. Mice received a laminectomy at T8, then the spinal column was stabilized using spinal clamps and positioned on an Infinite Horizon impactor device (Precision Systems and Instrumentation, Lexington, KY). The exposed spinal cord was visually aligned with the impactor tip and given a moderate (75 kDynes) contusion via computer-controlled delivery. All SCI mice received fluid supplements (Lactated Ringer's solution, 1 mL; Hospira, Inc., Lake Forest, IL), antibiotics (Baytril, Norbrook Laboratories Limited, Newry, Northern Ireland; 10 mg/kg), and analgesics (buprenorphine, 0.05 mg/kg) subcutaneously for the first week (twice per day) following surgery. Twice daily bladder expressions continued for the duration of the study. Locomotor recovery was assessed using the Basso Mouse Scale   21 open field test at 1 d and weekly after injury.
Eight-to ten-week old female rats weighing 180-200 g were anesthetized (ketamine/xylazine, 45 mg/5 mg/kg intraperitoneally) before receiving a moderate T8 contusive spinal cord injury (200 kDynes) using the Infinite Horizon impactor device (Precision Systems and Instrumentation, Lexington, KY) for rats. Lactated Ringer's solution (3 mL), and the same doses of Baytril and buprenorphine as described above were administered subcutaneously immediately post-surgery and then twice a day for 7 d. Twice-daily bladder expressions were performed until end of the study. All procedures were in accordance with University of Miami Institutional Animal Care and Use Committee and National Institutes of Health guidelines.
Histology
Mice or rats were perfused transcardially with cold phosphatebuffered saline (PBS) followed by 4% paraformaldehyde. Brains and spinal cords were harvested, post-fixed for 2 h and placed in 10%, 20%, 30% sucrose gradient overnight. An 8-mm mouse or 12-mm rat spinal segment centered at the injury site was embedded in Optimal Cutting Temperature compound compound (Tissue-Tek, Sakura Finetek USA, Inc., Torrance, CA) and sectioned on a cryostat. Sagittal or horizontal sections were cut serially at 10 lm and immunostained in PBS-0.3% TritonX-100 for mouse fibronectin (Millipore, Billerica, MA; AB2033, 1:500) or rat fibronectin (Millipore AB1954, 1:500), integrin a5b1 (Millipore MAB1984, 
Western blot
Mice were anesthetized (see above) and perfused transcardially with cold PBS. A 4-mm spinal segment centered at the injury site was dissected and meninges removed. Spinal cord tissues were then chopped into 100-lm slices using a McIlwain Tissue Chopper (Stoelting Co., Redding, CH) and lysed using a deoxycholate (DOC) extraction protocol as previously described. 22 Chopped tissue in freshly prepared 2% DOC lysis buffer (2% DOC, 20mM Tris.Cl, 2mM EDTA, 2mM iodoacetic acid, 2mM N-ethylmaleimide, 2mM PMSF) was passed through a 25G needle and centrifuged (4°C, 15,000g) to obtain DOC-soluble (supernatant) and DOC-insoluble (pellet) components. The DOC-insoluble pellet was solubilized in freshly prepared 1% SDS lysis buffer (1% SDS, 20mM Tris.Cl, 2mM EDTA, 2mM iodoacetic acid, 2mM N-ethylmaleimide, 2mM PMSF) and centrifuged (room temperature, 15,000 g) to obtain supernatant that contained DOC-insoluble ECM. Protein concentration was measured using bicinchoninic acid assay (Thermo Scientific, Waltham, MA). Protein sample from individual animals (mixed in b-mercaptoethanol) were separated on a 4-15% Criterion TGX precast gel (Bio-rad, Hercules, CA) and transferred onto a polyvinylidene difluoride (PVDF) membrane that was blocked in 5% milk (in Tris-Buffered Saline and Tween; Sigma-Aldrich, St. Louis, MO) TBS-T and incubated in rabbit anti-fibronectin antibody (Millipore AB2033, 1:2000) overnight at 4°C.
The next day, membranes were washed and incubated in appropriate HRP-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA; 1:50,000) and detected using chemiluminescent substrate (SuperSignal West Pico Thermo Scientific, Waltham, MA) and exposed to film. To control for loading variations, transferred PVDF membranes were incubated in 0.1% Coomassie blue R250 in 50% methanol/water for 30 min and de-stained in acetic acid/ethanol/water (1:5:4) for 20 min as previously described. 23 Band densities were quantified via ImageJ. Destained membrane was dried completely overnight and scanned. Each complete lane was then selected and band densities quantified using ImageJ 1.47v. Densities of fibronectin bands were normalized to densities of Coomassie blue (Supplementary Fig. 1 ; see online supplementary material at www.liebertpub.com).
qRT-PCR
Mice were anesthetized (see above) and perfused transcardially with cold diethylpyrocarbonate PBS. A 4-mm spinal segment centered at the injury site was dissected and homogenized and total ribonucleic acid (RNA) extracted using Qiagen RNeasy Plus Micro Kit. Total RNA was treated with DNAase (AMPD1; SigmaAldrich, St. Louis, MO) and complementary deoxyribonucleic acid (cDNA) synthesized using the Advantage RT-PCR Kit (ClonTech, Mountain View, CA). Quantitative polymerase chain reaction (qPCR) was performed using SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) and the Corbett Research RG 3000 thermal cycler (Qiagen, Valencia, CA). A standard curve was FIG. 1. Fibrotic scar formation after contusive spinal cord injury. In the uninjured spinal cord (A-D), fibronectin (red) expression and fibroblasts (green) are found only around blood vessels (D) and in the dura. At 3 d after injury (E-H), there is diffuse fibronectin expression throughout the injury site (E) while fibroblasts are not present in significant numbers (F). At 7 d (I-L), when fibroblasts densely populate the injury site ( J), the area of fibronectin expression closely matches that of fibroblasts (K) and appears more punctate (L). At 14 d (M-P, U-X), when the fibrotic scar has matured, it is characterized by a dense population of mostly fibroblasts and CD11b + leukocytes (W) and a fibronectin expression network that closely follows the distribution of fibroblasts throughout the injury site. This pattern continues at 28 d (Q-T). n = 5 per group. Scale bar in A, E, I, M, Q = 500 lm; in D, H, L, P, T = 50 lm; in U = 200 lm.
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ZHU ET AL. generated for each primer pair using serial dilutions of liver cDNA to optimize PCR conditions for each primer set. Expression level of each gene was calculated using the DDCt method and normalized to glyceraldehyde 3-phosphate dehydrogenase. Each sample was tested in triplicates. The primer sequences were: itga5 (forward: GGACCAAGACGGCTACAATGATGT, reverse: ACCTGGGAA GGTTTAGTGCTCAGT), itgb1 (forward: TTCAGACTTCCGCA TTGGCTTTGG, reverse: TGGGCTGGTGCAGTTTTGTTCAC), itgav (forward: GGGCCTATTGTTCAGCACAT, reverse: GATTC CACAGCCCAAAGTGT). The primer set for itgb3 was purchased from Qiagen (QT00128849, QuantiTect Primer Assay).
Quantification
Quantifications of immunohistochemical images were performed by unbiased observers. To quantify the number of a5b1 + cells that are also CD11b + or GFP + , co-localized cells were counted in three randomly selected 100 lm · 100 lm squares in the GFAP -region (fibrotic scar). Only DAPI + cells were counted. Colocalization was verified using Olympus FV10-ASW 3.0 viewer software to examine each of the ten one-micron Z-stack slices. For each animal, sections including the injury epicenter and two adjacent sagittal sections (spaced 100 lm apart) were quantified, and
Recombination rate in uninjured spinal cord of lysM-Cre mice. lysM-Cre/Rosa26-tdTomato mice demonstrate that approximately 34% of all microglia (CD11b) have undergone recombination (tdTomato) (A-E, K). A small percent of neurons (NeuN, 6%) also were labeled with tdTomato (F-J, K). Of all the cells that underwent recombination (tdTomato), approximately 66% were microglia and 33% were neurons (L). n = 3. Scale bar in A, F = 500 lm; in C, H = 50 lm. Error bars are standard error of the mean. the counts from each section were averaged. A total of 150-300 cells per animal were counted.
Quantification of the lysM tdTom cells in uninjured tissue were based on co-localization of the tdTomato reporter signal (enhanced using RFP antibody) with the following cell markers: CD11b, NeuN, GFAP and Olig2. Only DAPI + cells were counted. A total of 150-300 cells per animal were counted across at least three adjacent coronal sections (spaced 100 lm apart) of the thoracic spinal cord.
Results
Fibronectin matrix and fibroblasts have similar spatiotemporal distribution after SCI
Since the fibrotic scar is best characterized by regions of high fibronectin expression and fibroblast infiltration, we sought to determine the spatiotemporal relationship between fibronectin and fibroblasts after SCI. We utilized collagen1a1-GFP transgenic mice, which we have previously described as labeling perivascular fibroblasts in the spinal cord. 15 In the uninjured spinal cord, fibroblasts and fibronectin were found only around blood vessels and in the meninges (Fig. 1A-D) . At 3 d after injury, while fibronectin expression was increased, compared with uninjured spinal cord, its staining pattern was very diffuse throughout the injury site, suggesting that fibronectin had not yet formed into a fibrillar matrix. Importantly, fibroblasts were not present in significant number, suggesting that fibronectin was most likely from blood plasma and that the presence of fibronectin at this acute time point is not a reliable indicator of fibrotic scar formation (Fig. 1E-H) . However, at 7 d, there were a large number of fibroblasts present at the injury site and their distribution pattern closely matched that of fibronectin expression (Fig. 1I-L) . In addition, while fibronectin expression appeared very diffuse at 3 d after injury, it became much more condensed and fibrillar by 7 d, indicating that fibronectin was starting to form into a matrix. At 14 d, when the fibrotic scar has started to mature, fibronectin expression became much more organized into a fibrillar network that closely resembled the fibroblast distribution pattern (Fig. 1M-P, U-X) . At this time, CD11b
+ leukocytes also filled the fibrotic scar and were intimately associated with fibroblasts. This phenotype continued at 28 d (Fig. 1Q-T) .
Hence, these results demonstrate a matching distribution pattern between the fibronectin matrix and infiltration of perivascular fibroblasts at the injury site.
Fibroblasts are likely the primary source of fibronectin in the fibrotic scar Although the expression pattern of fibronectin suggests that fibroblasts are the source of fibronectin, it is possible that activated macrophages/microglia could also contribute. Thus, we sought to determine whether macrophages/microglia are a source of fibronectin by deleting fibronectin in these cells. The lysM-Cre knock-in mouse line expresses Cre recombinase in myeloid cells, including most macrophages and granulocytes. 24 While this mouse line has been well-characterized in terms of recombination in peripheral organs, no one has reported its recombination efficiency in mouse spinal cord. Thus, we used lysM tdTom mice (lysM-Cre mice crossed with Rosa26-tdTomato reporter mice) to determine the recombination efficiency of lysM-Cre in the uninjured spinal cord. We performed immunohistochemistry to co-label tdTomato with microglia (CD11b + ), neurons (NeuN + ), astrocytes (GFAP + ), and oligodendrocyte lineage cells (Olig2 + ). In the uninjured spinal cord, tdTomato labeled approximately 34% of all CD11b + microglia ( Fig. 2A-E, K) . This is in accordance with a recent report showing about 40% lysM-Cre efficiency in microglia isolated from uninjured spinal cord using flow cytometry. 25 This recombination efficiency for microglia is relatively low, compared with the 80-90% recombination efficiency reported for mature macrophages. 24 ,26 Surprisingly, we also observed around 6% of neurons that underwent recombination (Fig. 2F-J, K) . No tdTomato expression was observed in GFAP + or Oligo2 + cells (data not shown). Of all the tdTomato + cells, approximately 66% were microglia and the rest were neurons (Fig. 2L) .
Next, we injured lysM tdTom mice to determine the expression pattern of lysM-Cre recombinase after SCI. We found that the fibrotic scar (GFAP -area) was filled with tdTomato + cells (Fig. 3A-C) , suggesting that the recombination efficiency is very high in myeloid cells that occupy the fibrotic scar. We then performed SCI on lysM
Cre + /FN fl/fl mice (lysM-Cre mice crossed with floxed fibronectin mice). We found that while CD11b + cells were densely concentrated in the fibrotic scar (Fig. 3H, I ), there were no visible differences in fibronectin expression level, compared with Cre -controls (Fig. 3F, G) . Our results rule out macrophages/microglia as a major source of fibronectin and suggest that fibroblasts are most likely the primary source of fibronectin in the fibrotic scar.
Fibronectin matrix assembly after SCI
While the fibrillar organization of fibronectin at 7 d and beyond suggested its assembly into a matrix, we confirmed our observation using a biochemical approach by comparing the DOC-soluble and insoluble fractions of the injury site using western blot analysis. Fibronectin that has not assembled into a matrix is DOC-soluble, while matrix fibronectin is DOC-insoluble. In the uninjured spinal cord, both soluble and insoluble fibronectin were below detectable levels ( Fig. 4A, B; Supplementary Fig. 1 ), consistent with our immunohistochemistry results above (Fig. 1A) . There was a large increase in soluble fibronectin at 3 d after injury, peaking at 7 d and then dramatically decreasing at 14 and 28 d (Fig. 4A ; Supplementary Fig. 1 ). Insoluble fibronectin is indicated by multiple bands above the expected 250 kD monomer band. These multiple bands are present only in the insoluble fraction and contain fibronectin polymers that may be still in an interconnected matrix form. Insoluble fibronectin showed dramatic increases at 7 and 14 d after injury and decreased by 28 d (Fig. 4B; Supplementary Fig. 1 ). This suggests that soluble fibronectin expressed acutely after injury (3 d) is replaced by insoluble matrix fibronectin at later time points and that there is a decrease in overall fibronectin expression by 28 d after injury.
In addition to the multiple bands above 250 kD, there are 125 kD lower bands that are also only specific to the insoluble fraction from 7 through 28 d (Fig. 4B) . This temporal distribution coincides with fibronectin matrix formation revealed by immunohistochemistry (Fig. 1A, 1E , 1I, 1M, and 1Q), suggesting that the 125 kD bands may be proteolytic products of the fibronectin matrix, which is a result of ECM dynamics after SCI. Taken together, our data indicates that while fibronectin is highly expressed as early as 3 d after injury, its assembly into a matrix occurs at around 7 d when there is a large accumulation of fibroblasts and macrophages/microglia at the injury site.
Fibroblasts and macrophages/microglia express a5b1 fibronectin receptor
To investigate the mechanism of fibronectin matrix assembly, we studied the expression of a5b1 and aVb3 integrin receptors, which are the two major fibronectin receptors that have been described to participate in fibronectin assembly in vivo. [27] [28] [29] Using qRT-PCR, we found that in the uninjured spinal cord, a5 subunit had the lowest expression, compared with the other subunits (Fig. 5A) , confirming barely detectable levels of a5b1 immunoreactivity in uninjured spinal cord tissue sections (data not shown). However, after SCI, there was a 30-to 40-fold increase in a5 gene expression at 7 and 28 d after injury (Fig. 5B) . There also was a significant increase in b1 expression, while aV and b3 subunits showed an increasing trend that did not reach statistical significance (Fig. 5B) . Therefore, a5 and b1 expression showed the largest changes after injury and virtually all fibronectin co-localized with a5b1 (Fig. 5E-G) , suggesting that the a5b1 integrin receptor may be the primary fibronectin receptor after SCI. It should be noted, however, that not all a5b1 receptor colocalized with fibronectin, suggesting that this receptor may have functions other than fibronectin assembly in the fibrotic scar.
To determine the cell types that express a5b1, we performed immunohistochemistry to co-label a5b1 with different cellular markers. Since the fibrotic scar is comprised mainly of fibroblasts and immune cells, we focused on Col1a1-GFP + fibroblasts and CD11b + cells. Inside the fibrotic scar, approximately 80% and 20% of a5b1 + cells were CD11b + and Col1a1-GFP + , respectively (Fig.  5H-M, 5D ). Since most CD11b + cells are macrophages/microglia at this time after SCI, 30 our data suggests that activated macrophages/microglia may play a role in fibronectin matrix assembly in the fibrotic scar.
Fibrotic scar is present in injured rat spinal cord
To determine whether the fibrotic scar is present in a more clinically relevant animal model, we performed contusive SCI in rats, of which the pathological features are considered more similar to human SCI. 16, [31] [32] [33] At 56 d after injury, we assessed the injury site for fibronectin and PDGFR-b expression as markers for the fibrotic scar, because we demonstrated in our mouse model that fibronectin is abundantly present in the fibrotic scar (Fig. 1) and virtually all Col1a1-GFP + fibroblasts comprising the fibrotic scar express PDGFR-b. 15 Using immunohistochemistry, we detected intense immunoreactivity for fibronectin and PDGFR-b along the peripheral FIG. 5. Integrin receptor a5b1 is expressed by macrophages/microglia and fibroblasts after spinal cord injury (SCI). In the uninjured spinal cord, aV and b1 integrin subunit messenger RNA (mRNA) levels are higher than a5 and b3 (A, n = 3 per group). After SCI, both a5 and b1 mRNA are significantly increased, while aV and b3 mRNA levels are not significantly altered (B, n = 3 per group). Within the fibrotic scar at 14 d after injury (C), fibronectin is present mostly in regions of a5b1 expression (E-G), which is present on CD11b + macrophages/microglia (H-J, D; n = 3 per group) and fibroblasts (K-M, D; n = 3 per group). C, E, H, K are from different animals. Scale bar in C = 500 lm; in E, H, K = 50 lm. A: *p < 0.05 compared with a5, b3 using one way analysis of variance (ANOVA) with Tukey's post-test. B: *p < 0.05 compared with uninjured (uninj), #p < 0.05 compared with 7 d, two-way ANOVA with Bonferonni post-test. Error bars are standard error of the mean.
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rim of the cavities and outlining blood vessels in the surrounding spared tissue (Fig. 6 ) in rats. However, instead of taking up all GFAP -regions as in mice, the fibrotic scar in rats occupied a relatively smaller area at the injury site due to the distinct cavitation that has occurred in the fibrotic regions (Fig. 6C, D) . Note that the rat spinal cords are presented in horizontal sections as opposed to sagittal sections of mouse spinal cords shown above, so the morphologies of the injury site look different due to different observation planes. Similar to what is seen in mice, fibronectin and PDGFR-b had similar expression patterns at the rat injury site (Fig. 6C, D) . However, in sharp contrast to the non-overlapping staining pattern between fibronectin and GFAP in mice (Fig. 3D-G) , there was more overlap between GFAP + regions with fibronecin + and PDGFR-b + regions in rats (Fig. 6E, F) . Taken together, our findings indicate that the fibrotic scar is present in injured rat spinal cord, and suggest that it may also be present in injured human spinal cord.
Discussion
We sought to determine the mechanism of fibrotic scar formation after SCI by focusing on fibronectin matrix assembly. Our data indicate that while fibronectin is present at the injury site as early as 3 d after SCI, it starts to form a matrix around 7 d. This coincides with the time of peak fibroblast 15 and macrophage/microglia 34 infiltration, both of which express the prototypical fibronectin receptor integrin a5b1. We determined that activated macrophages/ microglia are not a source of fibronectin by deleting fibronectin in myeloid cells, suggesting that fibroblasts are likely the primary source of fibronectin after SCI. Finally, we demonstrate the presence of fibrotic scar markers such as fibronectin and PDGFR-b at the rat spinal cord injury site, suggesting that fibrotic scarring after SCI may be present across species.
Much of our knowledge of fibronectin comes from studies of cutaneous wound healing and peripheral organ fibrosis, in which fibronectin is suggested as a scaffolding protein that regulates ECM deposition and support cell adhesion, migration and survival. For example, in later phases of skin wound healing, the fibronectin matrix regulates deposition of other ECM molecules such as fibrinogen, collagen, laminin, chondroitin sulfate proteoglycan (CSPG), and tenascin-C. 35, 36 Fibronectin also is found to attract fibroblasts in glomerular fibrosis, 37 and support migration and survival of both circulating monocytes and microglia. [38] [39] [40] In central nervous system (CNS) injury, plasma fibronectin frequently is used as a component in biomaterial-based and/or cellbased grafts to facilitate cell migration, adhesion, and survival, and promote axon regeneration. [41] [42] [43] [44] Moreover, plasma fibronectin has been shown to have a neuroprotective role in brain injury 45 and ischemia. 46 Although fibronectin is the most commonly used marker of the fibrotic scar, virtually nothing is known about its role in the pathophysiology of SCI. Since fibronectin itself is neuroprotective and growth permissive for axons, why is the fibronectinabundant fibrotic scar so inhibitory to axon regeneration? A possible explanation would be that inhibitory molecules bind to the fibronectin matrix after SCI and result in an inhibitory environment in the fibrotic scar. This is supported by reports that the fibronectin matrix is closely associated with inhibitory proteins, such as NG2 proteoglycan and tenascin-C, in astrocytes/fibroblasts co-culture 4 and in SCI lesion epicenter. 47, 48 Further, fibronectin molecule has binding sites for the glycosaminoglycan chains of CSPGs and it has been demonstrated that CSPGs interact with fibronectin in vitro using various binding assays. [49] [50] [51] It is important to note that in order for these interactions to occur, fibronectin typically needs to form into a matrix, which we have demonstrated in this study. Therefore, understanding how the fibronectin matrix is assembled after SCI may allow us to target multiple inhibitory molecules in the fibrotic scar in order to promote axon regeneration.
Based on the functions of fibronectin described above, we hypothesize that fibronectin present at 3 d after SCI is most likely plasma fibronectin from blood, which is involved in formation of the provisional clot to stop bleeding. This provisional matrix provides a substrate for fibroblast and macrophage/microglia migration, which reaches a peak by 7 d. We propose that fibroblasts express cellular fibronectin that is assembled into a matrix mostly by macrophages/activated microglia. This peak in cellular migration also corresponds to peak soluble and insoluble fibronectin expression and regulation, as indicated by matrix assembly and degradation. At 14 d after injury, matrix fibronectin remains abundant while the level of soluble fibronectin significantly decreases, perhaps due to a combination of re-establishment of the blood-spinal cord barrier 52, 53 and degradation of plasma fibronectin by infiltrating cells. By 28 d after injury, matrix fibronectin levels also decline significantly and this could be due to a decrease in the number of fibroblasts at this time. 15 However, more functional studies are needed to support this working model.
For example, since it remains possible that fibroblasts simply assemble the fibronectin that is expressed by another cell type, future studies will need to delete fibronectin specifically in fibroblasts to address this issue. In addition, this loss-of-function study also will address what role, if any, fibronectin play in fibrotic scar formation. In addition, while the expression of a5b1 integrin mostly on macrophages/ microglia suggests that these cells might play a role in assembly of fibronectin into a matrix, a genetic deletion of the receptor specifically in these cells is necessary to reach a more firm conclusion.
Rat contusive SCI model is generally considered more relevant to human pathology than that of mouse. Unlike mouse contusive SCI, in which a profound fibrotic scar forms that fills up the entire lesion epicenter, rat injury site undergoes cavity formation that resembles human SCI patients. 31, 54 Because of this prominent cavitation, whether fibrotic scarring plays a role after human contusive SCI has received less attention. In our study using a rat model of contusive SCI, we clearly show that fibronectin + ECM and PDGFR-b + fibroblasts are present at the injury site, indicating that fibrotic scarring also occurs after rat SCI. However, in contrast to the distinct non-overlapping regions of fibronectin/PDGFR-b and GFAP expression in mice, there was some overlap of these regions in rats, suggesting that astrocytes may also play a role in fibrotic scarring rats and that there may be some differences in fibrotic mechanisms between the two species.
Moreover, given the observation that the fibrotic scar is always present along the cavity wall in rats, we could infer that a diminished fibrotic scarring may be the cause of the significant cavitation after rat SCI. This is in sharp contrast to the dense fibrotic scar in mice where cavitation does not happen. Whether this is the result of differences in the immune response between rats and mice or due to more direct differences in fibroblasts between the two species remains to be investigated.
In summary, our data indicates that fibronectin forms a matrix after SCI and that it is most likely expressed by fibroblasts at the injury site. In addition, we demonstrate that SCI in rats also leads to fibrotic scar formation (albeit to a lesser extent than in mice), suggesting that it also may be relevant to human SCI pathology.
